How to Contribute

The Atlas of Genetics and Cytogenetics in Oncology and Haematology does not publish research articles. The Atlas publishes reviews and "Case reports".

For complete Instructions, click here. In short, herein below:


The Atlas publishes "cards" (on hematological diseases, solid tumors, cancer-prone diseases, and genes), "deep insights", "case reports", and "educational items".

Please use the link "Submit Online" on the homepage to upload your manuscripts following the instructions given.
The article categories that can be submitted to the Atlas are the following:
-    Hematological chromosomal abnormalities
-    Hematological single entity
-    Hematological free review
-    Solid tumors- Simple pathologic entity
-    Solid tumors- Complex pathologic entity
-    Solid tumors- Free review
-    Solid tumors- Summary
-    Cancer-prone diseases
-    Genes in cancer
-    Educational items
-    Case reports 
-    Deep insights

1. Cards on hematology and solid tumors

For purpose of uniformity, the most recent World Health Organization (WHO) Classification of Hematological Diseases and Tumors will be followed but adapted were appropriate for the Atlas.  

There are different categories for submission in hematology and solid tumors. If you are interested in contributing or updating a card already present in the Atlas, please contact before our coordinator Dr. Ana E. Rodríguez, at, to avoid duplications.  

General TIPS:
o    Definition: it is not a properly an Abstract of the content. It can be used to report interesting review on the topic.
o    Please also supply key words.   
o    This is Atlas of Genetics, so pathologic findings must be summarized to essential in the Si, however, an example of key immunohistochemistry picture are welcome as a surrogate test for specific genetic marker.
o    Using figures from other published papers are allowed, but a permission from the publisher retaining the copyright is required.
o    Each contribution will be revised by editorial board member(s).
o    For a more detailed version, please check the “Instructions for authors”.

1.1     Hematology cards

           a) Hematological chromosomal abnormalities
Describe chromosome abnormalities, structural and numeric, which have been detected in a routine cytogenetic         analysis of patients with hematological disorders.

           b) Hematological single entity
Revision of entities included in the WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. The revision incorporates clinical features, morphology, immunophenotyping, cytogenetics, and molecular genetics to define disease entities of clinical significance.

          c) Hematological free review
Revision about widespread topics in the hematological field related with a single gene/fusion gene/chromosomal abnormalities which are in a group of different hematological entities or a general topic involving one or more entities that have in common a genetic marker.

Criteria of relevance of an entity:
- Chromosome structural aberrations: found in at least 2 cases in a given cancer, or in only 1 case if the hybrid gene is also described.
- Genes: fusion gene found in at least 1 cancer case, or gene mutation, amplification or homozygous deletion found in a significant subset of cases in a given cancer-type.
Subset of cases in a given cancer-type. with the same   gene fusion ?(instead of hybrid gene ), mutation amplification or homozygous deletion (what about biallelic)  

1.2     Solid tumors cards

            a) Summary
When possible, a summary of the ONLY genetic findings of a group of lesions having  in common the same cell of origin. Definition: it is not a properly an Abstract of the content. It can be used to report interesting review on the group of lesions. with PMID dealing mainly with recent reviews e.g. Soft tissue tumor:  Adipocytic tumors; Kidney: pediatric mesenchymal tumors; Vascular tumor of the bone.  Genetic findings will be summarized very briefly in Xcell Table for each lesions. Genetic information and mainly review article references are provided for well-characterized cytogenetic/molecular tumors investigated in more than a single case, with a few exceptions. Key immunohistochemistry data are welcome as a surrogate test for a specific genetic marker.
The summary will be uploaded as Xcell, see the instructions, and periodically updated when needed, according to new important papers appearing in the literature. If a more comprehensive review for each entity/specific rearrangement is available in the Atlas, such”links” it will be highlighted.

            b) Single pathologic entity
Each pathological entity with already a detailed review will be highlighted in each specific WHO list. Only the recent detailed review card will be linked. If you are interested in contributing to summarize a single entity, not yet reported in the Atlas, please contact BEFORE our coordinator Dr. Ana Rodriguez at, so we will not have duplications.  Please remember to check WHO books for the correct official name of the entity and corresponding ICD-0 code, if you cannot find please contact us.
This is Atlas of Genetics, so pathologic findings must be summarized to essential, however, an example of a key immunohistochemistry picture is welcome as a surrogate test for a specific genetic marker, or specific pathologic clue to recognize the entity. Therefore, the readers can use such clues if they cannot use any genetic tools

           c) Complex pathologic entity

Genetic data are more complex in the most common tumors e.g. lung, breast, prostate, and there is a need of additional tables and figures to describe the complexity of the genetic markers (e.g. Gastro-intestinal tumors). Tables, figures, diagrams to summarize data are welcome

            d) Free review
This template can be used in a very widespread of the topic in solid tumors dealing with:
                o    gene/rearrangement promiscuity in a group of different tumors e.g.
                o    Specific treatment of any genetic marker in one or more entity(ies)
                o    Immunohistochemistry for genetic markers
                o    Specific technology for picking up a genetic marker
                o    Any general topic involving an entity or more entities having in common genetic marker
It will not have a specific ICD-0 code and you can use as you what the free space with tables, figures, diagrams. See details out to upload your contribution in the instructions for authors.

Definition: in such cases, it will be more as Abstract, a summary of the topic. Please also supply key words.

2. Cancer-prone disease cards

Significant aggregation of genetic disorders in which inherited genetic mutations in one or more genes predisposes the affected individuals to the early onset development of cancers

3. Genes in cancer cards

Please, use Hugo names (HGNC official nomenclature), with the usual name in brackets if necessary: avoid the most confusing "p21", erk", or "mek".
You will find official gene names at

4. Deep insights

These papers do not follow the above-mentioned patterns; they are written as traditional papers, made of paragraphs with headings, at the author's convenience.

5. Case Reports

This section is dedicated to case reports dealing with new as well as recurrent -but rare- chromosomes abnormalities in leukemias, lymphomas, and solid tumors.

Case Reports serve important purposes: from communicating the discovery of a new chromosome aberration to confirming a recurrent, but rare, abnormality. They can also be a mean to providing new clinical and therapeutic data concerning recurrent chromosome abnormalities. A single laboratory may see a new translocation associated with a neoplasm only once. Communicating this finding to others can be useful to discover more of such cases and provide the platform for larger studies, which could lead to the discovery of new genes involved in the development and/or progression of various neoplasms. When essential information is provided, case reports have the potential to be highly readable and as such have a significant impact on subsequent clinical research.


Authors should, in a couple of sentences, describe why the submitted case report should be considered for acceptance in the Atlas.
1. Cases of interest shall be:
a) new (previously unreported);
b) recurrent (i.e. previously described in at least 1 case; maximum 3 cases);
c) additional cases as part of a large series may be accepted only if they provide additional clinical and therapeutic information;
d) Contain well-documented clinics and laboratory findings.
2. Provide iconography relating to the chromosome aberration(s). If FISH or microarray was performed, provide those images for the reviewers and for the publication: in NO case will a case report be accepted without the karyotype and/or FISH and/or microarray (if performed).
The informed consent is compulsory. A template of an informed consent can be found here.

6. Educational Items

Must be didactic, give full information and be accompanied with iconography.

Please, contact us before undertaking any work, to avoid double (conflicting) reports.


It is possible to send only images (i e: karyotype, FISH analysis, etc) accompanied by a legend. We are still working how to present such items and link to the existing cards in the Atlas. More details will be available soon.

Conflicts of Interest

Authors must state explicitly whether potential conflicts do or do not exist. Reviewers must disclose to editors any conflicts of interest that could bias their opinions of the manuscript. The editor and the editorial board members must disclose any potential conflict. See Editorial Ethics.

Privacy and Confidentiality – Iconography

Patients have a right to privacy. Identifying details should be omitted. If complete anonymity is difficult to achieve, informed consent should be obtained. See Editorial Ethics.

Creative Commons

This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 2.0 France License.

Creative Commons License